These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 1376768

  • 1. Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera.
    Pither RJ, Nolan L, Tarlton J, Walford J, Morgan AJ.
    J Gen Virol; 1992 Jun; 73 ( Pt 6)():1409-15. PubMed ID: 1376768
    [Abstract] [Full Text] [Related]

  • 2. Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.
    Pither RJ, Zhang CX, Shiels C, Tarlton J, Finerty S, Morgan AJ.
    J Virol; 1992 Feb; 66(2):1246-51. PubMed ID: 1370550
    [Abstract] [Full Text] [Related]

  • 3. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
    Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE, Morgan AJ.
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
    [Abstract] [Full Text] [Related]

  • 4. Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.
    Wallace LE, Wright J, Ulaeto DO, Morgan AJ, Rickinson AB.
    J Virol; 1991 Jul; 65(7):3821-8. PubMed ID: 1710291
    [Abstract] [Full Text] [Related]

  • 5. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE, Coinçon M, Leblond V, Hu J, Fang JM, Sygusch J, Alfieri C.
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [Abstract] [Full Text] [Related]

  • 6. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
    Ulaeto D, Wallace L, Morgan A, Morein B, Rickinson AB.
    Eur J Immunol; 1988 Nov; 18(11):1689-97. PubMed ID: 2904885
    [Abstract] [Full Text] [Related]

  • 7. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
    Yao QY, Rowe M, Morgan AJ, Sam CK, Prasad U, Dang H, Zeng Y, Rickinson AB.
    Int J Cancer; 1991 Apr 22; 48(1):45-50. PubMed ID: 1850382
    [Abstract] [Full Text] [Related]

  • 8. Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220.
    Qualtiere LF, Decoteau JF, Hassan Nasr-el-Din M.
    J Gen Virol; 1987 Feb 22; 68 ( Pt 2)():535-43. PubMed ID: 2434608
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mapping of the epitopes of Epstein-Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants.
    Zhang PF, Klutch M, Armstrong G, Qualtiere L, Pearson G, Marcus-Sekura CJ.
    J Gen Virol; 1991 Nov 22; 72 ( Pt 11)():2747-55. PubMed ID: 1719128
    [Abstract] [Full Text] [Related]

  • 14. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
    Lee SP, Wallace LE, Mackett M, Arrand JR, Searle PF, Rowe M, Rickinson AB.
    Int Immunol; 1993 May 22; 5(5):451-60. PubMed ID: 8391306
    [Abstract] [Full Text] [Related]

  • 15. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines.
    Wilson AD, Lövgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ.
    Vaccine; 1999 Mar 05; 17(9-10):1282-90. PubMed ID: 10195641
    [Abstract] [Full Text] [Related]

  • 16. Effect of monoclonal antibodies to Epstein-Barr virus envelope glycoproteins on Epstein-Barr virus neutralization and binding to target cell receptors. A comparative analysis.
    Stocco R, Sauvageau G, Stefanescu I, Menezes J.
    Intervirology; 1990 Mar 05; 31(5):295-300. PubMed ID: 1703135
    [Abstract] [Full Text] [Related]

  • 17. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin.
    Ragot T, Finerty S, Watkins PE, Perricaudet M, Morgan AJ.
    J Gen Virol; 1993 Mar 05; 74 ( Pt 3)():501-7. PubMed ID: 8383183
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Identification of T- and B-cell epitopes associated with a restricted component of the Epstein-Barr virus-induced early antigen complex.
    Pothen S, Cao T, Smith R, Levine PH, Levine A, Pearson GR.
    Int J Cancer; 1993 Jan 21; 53(2):199-204. PubMed ID: 7678829
    [Abstract] [Full Text] [Related]

  • 20. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
    Geerligs HJ, Kocken CH, Drijfhout JW, Weijer WJ, Bloemhoff W, Wilterdink JB, Welling GW, Welling-Wester S.
    J Gen Virol; 1990 Aug 21; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.